Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pitavastatin + ezetimibe + amlodipine + valsartan
- Development stage
- Unknown
- Lead developer
- JW Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
pitavastatin + ezetimibe + amlodipine + valsartan is a four-drug fixed-dose combination (FDC) therapy being developed by JW Jungwoo Pharmaceutical for the management of patients with both hyperlipidemia and hypertension. This 4-in-1 small molecule combination integrates four distinct mechanisms of action: pitavastatin, an HMG-CoA reductase inhibitor (statin) that reduces endogenous cholesterol synthesis; ezetimibe, which inhibits the Niemann-Pick C1-like 1 (NPC1L1) protein to block intestinal cholesterol absorption; amlodipine, a dihydropyridine calcium channel blocker (CCB) that induces vasodilation; and valsartan, an angiotensin II receptor blocker (ARB) that inhibits the renin-angiotensin-aldosterone system. By combining these agents into a single tablet, the therapy aims to improve medication adherence and provide synergistic control of blood pressure and lipid levels, thereby reducing the overall risk of cardiovascular disease. The product is currently in Phase 3 clinical trials.
- Brand names
- LIVALOZET HI
- Other names
- 4-in-1: Pitavastatin/Ezetimibe/Amlodipine/Valsartan
02
Targets
NPC1L1 (Niemann-pick C1-Like 1 transporter)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on pitavastatin + ezetimibe + amlodipine + valsartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pitavastatin + ezetimibe + amlodipine + valsartan.